



**Joint Statement in Response to the Draft Report of the Expert Panel on Comprehensive Measures
for Prompt and Stable Supply of Pharmaceuticals**

6 June 2023

Japan Pharmaceutical Manufacturers Association (JPMA)

Pharmaceutical Research and Manufacturers of America (PhRMA)

European Federation of Pharmaceutical Industries and Associations (EFPIA Japan)

Today, the Expert Panel on Comprehensive Measures to Achieve Rapid and Stable Supply of Pharmaceuticals (hereinafter “Expert Panel”), organized by the Ministry of Health, Labour and Welfare, presented the draft report on various issues related to the pharmaceutical industry in Japan and recommendations regarding the direction of future policy reforms.

To date, the three pharmaceutical trade associations representing Japan, the United States, and Europe have pointed out that a drug lag and drug losses have been occurring in reality, and have raised concerns that innovation is not properly valued, drug prices are not maintained during the patent period, and the system is unpredictable, among other issues with the drug pricing system.

We appreciate the fact that these issues were captured and the general direction for their resolution was presented by the Expert Panel.

It is critical that pharmaceutical innovations are widely and appropriately valued and rewarded in the drug pricing system, and that the scope of evaluation be in line with global standards so that innovation is recognized for more than a few drugs or company size categories. We believe that the appropriate evaluation will allow us to quickly recover our investment costs and reinvest in the next stage of R&D, ultimately creating an attractive market and accelerating innovation.

Based on the Expert Panel draft report, we understand that in-depth discussions on each issue for implementation will begin. We strongly hope that specific measures to resolve the issues will be clearly demonstrated.

We will actively participate in future discussions and respond to the expectations of the people in Japan. We are committed to doing our utmost to regain the sustainable growth of the market in Japan through collaboration between industry, academia, and government, further strengthen our drug discovery capabilities, and remain the global leader in life science field.